Chris Sturgeon

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.